NeuroPace Concluded Recruitment for Epilepsy Treatment Trial

Enrolment in a critical study exploring NeuroPace’s nerve activity treatment for idiopathic generalized epilepsy has been successfully concluded. 

The medical technology firm reported that it had surpassed its intake target by more than 25%.  

The RNS device from NeuroPace is being used by the study group as a treatment to help reduce primary generalized seizures. Idiopathic generalized epilepsy is a neurological disorder characterized by recurrent seizures of undetermined origin, affecting both hemispheres of the brain, and typically manifesting as generalized tonic-clonic seizures. 

The device, with the use of electrodes, can identify when a seizure is about to start and then minimize its severity by giving brief electrical stimulation impulses. 

Dr Martha Morrell, the leading medical executive, commented, “We believe that the pace of enrolment in the trial highlights the significant unmet need that exists for patients with drug refractory idiopathic generalised epilepsy.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.